Presage's CIVO technology enables, for the first time, simultaneous evaluation and comparison of multiple anti-cancer drugs, drug candidates, and drug combinations directly in a patient’s tumor, without toxicities associated with typical clinical drug exposures, addressing the issue of new drugs being tested in laboratory models of cancer that do not accurately represent the complexity of the human tumor microenvironment and therefore do not reliably predict patient benefit in the clinic, resulting in overwhelming percentage of clinical failures and tremendous cost to drug developers and patients in need of new therapy options.